Steven G Dubois

List of Publications by Year in Descending Order

82 papers	2,203 citations	26 h-index	45 g-index
88 ext. papers	2,825 ext. citations	6.2 avg, IF	4.86 L-index

#	Paper	IF	Citations
82	Reply to J.-G. Wang et al.. *Journal of Clinical Oncology*, **2022**, JCO2102922	2.2	
81	High-Risk and Relapsed Neuroblastoma: Toward More Cures and Better Outcomes.. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2022**, 42, 1-13	7.1	1
80	Belzutifan, a Potent HIF2 Inhibitor, in the Pacak-Zhuang Syndrome. *New England Journal of Medicine*, **2021**, 385, 2059-2065	59.2	4
79	Phase III Trial Adding Vincristine-Topotecan-Cyclophosphamide to the Initial Treatment of Patients With Nonmetastatic Ewing Sarcoma: A Children Oncology Group Report. *Journal of Clinical Oncology*, **2021**, JCO2100358	2.2	8
78	NUT Carcinoma Without Upfront Surgical Resection: A Case Report. *Journal of Pediatric Hematology/Oncology*, **2021**, 43, e707-e710	1.2	1
77	The Impact of COVID-19 on Clinical Trial Execution at the Dana-Farber Cancer Institute. *Journal of the National Cancer Institute*, **2021**, 113, 1453-1459	9.7	21
76	Patterns of Translocation Testing in Patients Enrolling in a Cooperative Group Trial for Newly Diagnosed Metastatic Ewing Sarcoma. *Archives of Pathology and Laboratory Medicine*, **2021**, 145, 1564-1568	5	0
75	Retrospective evaluation of single patient investigational new drug (IND) requests in pediatric oncology. *Cancer Medicine*, **2021**, 10, 2310	4.8	2
74	Ewing Sarcoma-Diagnosis, Treatment, Clinical Challenges and Future Perspectives. *Journal of Clinical Medicine*, **2021**, 10,	5.1	23
73	Population Pharmacokinetics of Sunitinib and its Active Metabolite SU012662 in Pediatric Patients with Gastrointestinal Stromal Tumors or Other Solid Tumors. *European Journal of Drug Metabolism and Pharmacokinetics*, **2021**, 46, 343-352	2.7	0
72	Derivation and validation of risk groups in patients with osteosarcoma utilizing regression tree analysis. *Pediatric Blood and Cancer*, **2021**, 68, e28834	3	1
71	Stereotactic Body Radiation Therapy for Metastatic and Recurrent Solid Tumors in Children and Young Adults. *International Journal of Radiation Oncology Biology Physics*, **2021**, 109, 1396-1405	4	3
70	Extrapolation of pharmacokinetics and pharmacodynamics of sunitinib in children with gastrointestinal stromal tumors. *Cancer Chemotherapy and Pharmacology*, **2021**, 87, 621-634	3.5	1
69	Randomized Phase II Trial of MIBG Versus MIBG, Vincristine, and Irinotecan Versus MIBG and Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A Report From NANT Consortium. *Journal of Clinical Oncology*, **2021**, 39, 3506-3514	2.2	7
68	Multicenter Analysis of Genomically Targeted Single Patient Use Requests for Pediatric Neoplasms. *Journal of Clinical Oncology*, **2021**, 39, 3822-3828	2.2	0
67	Decitabine and Vorinostat with Chemotherapy in Relapsed Pediatric Acute Lymphoblastic Leukemia: A TACL Pilot Study. *Clinical Cancer Research*, **2020**, 26, 2297-2307	12.9	12
66	The Evolving Diagnostic and Treatment Landscape of NTRK-Fusion-Driven Pediatric Cancers. *Paediatric Drugs*, **2020**, 22, 189-197	4.2	4

65	Physiologically Based Pharmacokinetic Modeling and Simulation of Sunitinib in Pediatrics. *AAPS Journal*, **2020**, 22, 31	3.7	3
64	An Anatomical Site and Genetic-Based Prognostic Model for Patients With Nuclear Protein in Testis (NUT) Midline Carcinoma: Analysis of 124 Patients. *JNCI Cancer Spectrum*, **2020**, 4, pkz094	4.6	49
63	Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial. *Lancet Oncology, The*, **2020**, 21, 121-133	21.7	93
62	The use of interval-compressed chemotherapy with the addition of vincristine, irinotecan, and temozolomide for pediatric patients with newly diagnosed desmoplastic small round cell tumor. *Pediatric Blood and Cancer*, **2020**, 67, e28559	3	6
61	Trends in conditional survival and predictors of late death in neuroblastoma. *Pediatric Blood and Cancer*, **2020**, 67, e28329	3	1
60	Off-label prescribing of targeted anticancer therapy at a large pediatric cancer center. *Cancer Medicine*, **2020**, 9, 6658-6666	4.8	6
59	The RACE to accelerate drug development for children with cancer. *The Lancet Child and Adolescent Health*, **2020**, 4, 714-716	14.5	4
58	Landscape of phase 1 clinical trials for minors with cancer in the United States. *Pediatric Blood and Cancer*, **2020**, 67, e28694	3	1
57	DICER1-associated central nervous system sarcoma in children: comprehensive clinicopathologic and genetic analysis of a newly described rare tumor. *Modern Pathology*, **2020**, 33, 1910-1921	9.8	16
56	Sponsorship of oncology clinical trials in the United States according to age of eligibility. *Cancer Medicine*, **2020**, 9, 4495-4500	4.8	7
55	Timing of first-in-child trials of FDA-approved oncology drugs. *European Journal of Cancer*, **2019**, 112, 49-56	7.5	33
54	Winning the RACE: Expanding pediatric cancer drug approvals. *Pediatric Blood and Cancer*, **2019**, 66, e27305	3	6
53	Ushering in the next generation of precision trials for pediatric cancer. *Science*, **2019**, 363, 1175-1181	33.3	27
52	Predictors of differential response to induction therapy in high-risk neuroblastoma: A report from the Children's Oncology Group (COG). *European Journal of Cancer*, **2019**, 112, 66-79	7.5	23
51	Second malignancies in patients treated for Ewing sarcoma: A systematic review. *Pediatric Blood and Cancer*, **2019**, 66, e27938	3	4
50	A Novel Fusion in Pediatric Medullary Thyroid Carcinoma. *Thyroid*, **2019**, 29, 1704-1707	6.2	10
49	Duality of purpose: Participant and parent understanding of the purpose of genomic tumor profiling research among children and young adults with solid tumors. *JCO Precision Oncology*, **2019**, 3,	3.6	7
48	Risk stratification by somatic mutation burden in Ewing sarcoma. *Cancer*, **2019**, 125, 1357-1364	6.4	13

47	Clinical Impact of Tumor Mutational Burden in Neuroblastoma. *Journal of the National Cancer Institute*, **2019**, 111, 695-699	9.7	16
46	Phase I study of vorinostat in combination with isotretinoin in patients with refractory/recurrent neuroblastoma: A new approaches to Neuroblastoma Therapy (NANT) trial. *Pediatric Blood and Cancer*, **2018**, 65, e27023	3	22
45	Detection of circulating tumour DNA is associated with inferior outcomes in Ewing sarcoma and osteosarcoma: a report from the Children's Oncology Group. *British Journal of Cancer*, **2018**, 119, 615-621	8.7	47
44	Age dependency of primary tumor sites and metastases in patients with Ewing sarcoma. *Pediatric Blood and Cancer*, **2018**, 65, e27251	3	18
43	Neuroblastoma and Histone Demethylation. *New England Journal of Medicine*, **2018**, 379, 1476-1477	59.2	1
42	The use of neoadjuvant larotrectinib in the management of children with locally advanced TRK fusion sarcomas. *Cancer*, **2018**, 124, 4241-4247	6.4	75
41	Comparison of Epidemiology, Clinical Features, and Outcomes of Patients with Reported Ewing Sarcoma and PNET over 40 Years Justifies Current WHO Classification and Treatment Approaches. *Sarcoma*, **2018**, 2018, 1712964	3.1	10
40	Dual HDAC and PI3K Inhibition Abrogates NFB- and FOXM1-Mediated DNA Damage Response to Radiosensitize Pediatric High-Grade Gliomas. *Cancer Research*, **2018**, 78, 4007-4021	10.1	36
39	Patterns of Relapse in High-Risk Neuroblastoma Patients Treated With and Without Total Body Irradiation. *International Journal of Radiation Oncology Biology Physics*, **2017**, 97, 270-277	4	20
38	Clinical Cancer Advances 2017: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. *Journal of Clinical Oncology*, **2017**, 35, 1341-1367	2.2	75
37	MIBG avidity correlates with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group. *Pediatric Blood and Cancer*, **2017**, 64, e26545	3	25
36	Correlation of Ezrin Expression Pattern and Clinical Outcomes in Ewing Sarcoma. *Sarcoma*, **2017**, 2017, 8758623	3.1	2
35	Association of MYCN copy number with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group. *Cancer*, **2017**, 123, 4224-4235	6.4	73
34	Pediatric NUT-midline carcinoma: Therapeutic success employing a sarcoma based multimodal approach. *Pediatric Hematology and Oncology*, **2017**, 34, 231-237	1.7	20
33	Phase 1 study of sirolimus in combination with oral cyclophosphamide and topotecan in children and young adults with relapsed and refractory solid tumors. *Oncotarget*, **2017**, 8, 23851-23861	3.3	10
32	Patient/parent perspectives on genomic tumor profiling of pediatric solid tumors: The Individualized Cancer Therapy (iCat) experience. *Pediatric Blood and Cancer*, **2016**, 63, 1974-82	3	32
31	Reply: Is Extended Sedation Necessary for Young Children Receiving High-Dose (131) I-MIBG Therapy?. *Pediatric Blood and Cancer*, **2016**, 63, 1868	3	
30	Evaluation and Outcome of Central Nervous System Involvement in Pediatric Acute Lymphoblastic Leukemia in Dar es Salaam, Tanzania. *Pediatric Blood and Cancer*, **2016**, 63, 458-64	3	0

29	Extended Sedation With Continuous Midazolam or Dexmedetomidine Infusion for Young Children Receiving 131 I-MIBG Radiopharmaceutical Therapy for Advanced Neuroblastoma. *Pediatric Blood and Cancer*, **2016**, 63, 471-8	3	7
28	Multicenter Feasibility Study of Tumor Molecular Profiling to Inform Therapeutic Decisions in Advanced Pediatric Solid Tumors: The Individualized Cancer Therapy (iCat) Study. *JAMA Oncology*, **2016**, 2, 608-615	13.4	128
27	Three-dimensional Radiologic Assessment of Chemotherapy Response in Ewing Sarcoma Can Be Used to Predict Clinical Outcome. *Radiology*, **2016**, 280, 905-15	20.5	26
26	Increased risk of second malignant neoplasms in adolescents and young adults with cancer. *Cancer*, **2016**, 122, 116-23	6.4	88
25	Impact of Two Measures of Micrometastatic Disease on Clinical Outcomes in Patients with Newly Diagnosed Ewing Sarcoma: A Report from the Children's Oncology Group. *Clinical Cancer Research*, **2016**, 22, 3643-50	12.9	18
24	A Phase I Study of Quizartinib Combined with Chemotherapy in Relapsed Childhood Leukemia: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study. *Clinical Cancer Research*, **2016**, 22, 4014-22	12.9	43
23	Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial. *Journal of Clinical Oncology*, **2016**, 34, 1368-75	2.2	83
22	Clinical Characteristics and Outcomes of Pediatric Patients with Desmoplastic Small Round Cell Tumor. *Rare Tumors*, **2016**, 8, 6145	1.1	20
21	Comparison of clinical features and outcomes in patients with extraskeletal versus skeletal localized Ewing sarcoma: A report from the Children's Oncology Group. *Pediatric Blood and Cancer*, **2016**, 63, 1771-9	3	61
20	Assessment of extent of surgical resection of primary high-grade osteosarcoma by treating institutions: A report from the Children's Oncology Group. *Journal of Surgical Oncology*, **2016**, 113, 351-4	2.8	8
19	Conditional Survival and Predictors of Late Death in Patients With Ewing Sarcoma. *Pediatric Blood and Cancer*, **2016**, 63, 1091-5	3	13
18	Current state of pediatric sarcoma biology and opportunities for future discovery: A report from the sarcoma translational research workshop. *Cancer Genetics*, **2016**, 209, 182-94	2.3	29
17	Identification of Discrete Prognostic Groups in Ewing Sarcoma. *Pediatric Blood and Cancer*, **2016**, 63, 47-53	3	38
16	Intraoperative radiotherapy and limb-sparing surgery in the treatment of primary, non-metastatic extremity soft tissue sarcoma. *Journal of Radiation Oncology*, **2015**, 4, 299-307	0.7	
15	Second malignant neoplasms among children, adolescents and young adults with Wilms tumor. *Pediatric Blood and Cancer*, **2015**, 62, 1259-64	3	21
14	Clinical features and outcomes of infants with Ewing sarcoma under 12 months of age. *Pediatric Blood and Cancer*, **2015**, 62, 1947-51	3	11
13	Clinical, biologic, and prognostic differences on the basis of primary tumor site in neuroblastoma: a report from the international neuroblastoma risk group project. *Journal of Clinical Oncology*, **2014**, 32, 3169-76	2.2	106
12	Circulating endothelial cells and circulating endothelial precursor cells in patients with osteosarcoma. *Pediatric Blood and Cancer*, **2012**, 58, 181-4	3	15

11	Evaluation of polymorphisms in EWSR1 and risk of Ewing sarcoma: a report from the Childhood Cancer Survivor Study. *Pediatric Blood and Cancer*, **2012**, 59, 52-6	3	6
10	Tolerability and pharmacokinetic profile of a sunitinib powder formulation in pediatric patients with refractory solid tumors: a Children℞s Oncology Group study. *Cancer Chemotherapy and Pharmacology*, **2012**, 69, 1021-7	3.5	27
9	Clinical features and outcomes in patients with extraskeletal Ewing sarcoma. *Cancer*, **2011**, 117, 3027-32	6.4	140
8	Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: a children℞s oncology group study. *Clinical Cancer Research*, **2011**, 17, 5113-22	12.9	92
7	Phase II study of intermediate-dose cytarabine in patients with relapsed or refractory Ewing sarcoma: a report from the Children℞s Oncology Group. *Pediatric Blood and Cancer*, **2009**, 52, 324-7	3	61
6	Late recurrence of ewing sarcoma during pregnancy: a report of 2 cases. *Journal of Pediatric Hematology/Oncology*, **2008**, 30, 716-8	1.2	6
5	Lung metastases in neuroblastoma at initial diagnosis: A report from the International Neuroblastoma Risk Group (INRG) project. *Pediatric Blood and Cancer*, **2008**, 51, 589-92	3	45
4	Remarkable Activity of Bortezomib Combined with Chemotherapy in a Phase I Study of Relapsed Childhood Acute Lymphoblastic Leukemia (ALL). A Report from the Therapeutic Advances in Childhood Leukemia (TACL) Consortium.. *Blood*, **2008**, 112, 1919-1919	2.2	3
3	Markers of angiogenesis and clinical features in patients with sarcoma. *Cancer*, **2007**, 109, 813-9	6.4	115
2	Hematologic toxicity of high-dose iodine-131-metaiodobenzylguanidine therapy for advanced neuroblastoma. *Journal of Clinical Oncology*, **2004**, 22, 2452-60	2.2	92
1	Pediatric acute blastic natural killer cell leukemia. *Leukemia and Lymphoma*, **2002**, 43, 901-6	1.9	20